COMMUNIQUÉS West-GlobeNewswire

DCI Edge Introduces Series 5 Plus Dental Stools with 13° Anterior-Tilt Seat and Patent-Pending Brake
07/10/2026
New clinician's and assistant's stools, from DCI Edge, pair anti-slip Edge Upholstery with a 300 lb. capacity and a 10-year warranty. Newberg, OR, Oct. 07, 2026 (GLOBE NEWSWIRE) -- DCI Edge has released the Series 5 [...]
Childhood cancer treatment success reaches 87%, says Medicana specialist
07/10/2026
Professor Tezer Kutluk points to six decades of progress and the growing role of personalised treatment, while warning that access to care still determines children’s chances ISTANBUL, Türkiye, Oct. 07, 2026 (GLOBE [...]
Raw Garden Launches a Higher Standard in Distillate All-In-One
07/10/2026
"Disti Made Different" New 1-gram AIO brings Raw Garden's clean cannabis standard to an everyday price, in 12 strain-inspired flavors SANTA BARBARA, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Raw Garden , one of [...]
Alignment Health Expands to Three New California Counties and Adds Hoag and Astrana Health for 2027
07/10/2026
Growth into Kern, Kings and Tulare counties and an expanded provider network give California Medicare beneficiaries more local care options ORANGE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Alignment Health Plan, an [...]
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
07/10/2026
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 2 1 SD is most prevalent type of chronic inducible urticaria (CIndU) 2 [...]
BrewDog’s Winning Streak Rolls on with Gold at the Scottish Beer Awards
07/10/2026
Hazy Jane Tropical and Krush Test Dummy take Gold as BrewDog builds on its recent sweep at the 2026 World Beer Awards. ELLON, Scotland, Oct. 07, 2026 (GLOBE NEWSWIRE) -- BrewDog , a leader in U.K. craft beer and one of [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
07/10/2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 7 octobre 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Ipsen - Septembre 2026 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/10/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Ipsen - September 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/10/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
07/10/2026
Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting. At the Extraordinary General Meeting the proposal from the Board of [...]
Greenline Expands to Retail with Pajaro Dispensary Grand Opening and Ribbon Cutting on Friday, October 9
07/10/2026
Vertically Integrated Monterey Bay Cultivator Brings Award-Winning Indoor Strains—Including ‘Orange Tree’—Directly to Watsonville Shelves at Grower-Direct Prices WATSONVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- [...]
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes
07/10/2026
– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today [...]
BrewDog Rallies Beer Lovers Across the UK to Choose Craft
07/10/2026
Bold UK-wide campaign puts craft beer back at the centre of culture, celebrating better ingredients, better quality, skilled brewers, beer lovers and the big flavours that make craft worth choosing. BrewDog consumers [...]
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
07/10/2026
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no [...]
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
07/10/2026
Caregivers say they need clearer pain management plans, earlier education, and practical support on non-opioid options before a loved one undergoes surgery BRISBANE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Pacira [...]
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
07/10/2026
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that [...]
Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
07/10/2026
Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2 Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia [...]
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
07/10/2026
REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative [...]
Atsena Presents Positive Preliminary Safety and Efficacy Results from Parts A and B of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
07/10/2026
ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has defined as supportive of potential approval Atsena also reported new data [...]

Pages